Lilly Expands Indiana Manufacturing With $4.5 Billion Investment

Eli Lilly and Company has announced an additional $4.5 billion investment in its Lebanon, Indiana manufacturing operations, strengthening the pharmaceutical giant’s long-term commitment to U.S.-based drug production and advanced therapies. The latest expansion brings Lilly’s total capital commitments in Indiana since 2020 to more than $21 billion and its nationwide manufacturing investments to over $50 billion.

The new funding will be directed toward two facilities on Lilly’s Lebanon campus: Lilly Lebanon API and Lilly Lebanon Advanced Therapies. The investment is aimed at supporting the company’s growing pipeline of medicines and increasing global demand for treatments in obesity, diabetes and genetic diseases.

Lilly officially opened its Lebanon Advanced Therapies facility, which will serve as the company’s first dedicated manufacturing site for genetic medicines. The facility is designed to support both clinical and commercial production of therapies that target diseases at the genetic level, including a wide range of advanced medicine technologies from early research through large-scale supply.

Company executives said the site required the development of entirely new manufacturing systems due to the absence of established commercial standards for many genetic medicine modalities. The Lebanon campus will eventually include three major facilities: Lebanon Advanced Therapies, Lebanon API and the Lilly Medicine Foundry.

The company also confirmed that its Lebanon API site will manufacture several major obesity and diabetes treatments, including Zepbound® and Mounjaro®, which are among the most prescribed injectable medicines for weight management and type 2 diabetes. Lilly plans to further expand production capabilities to include Foundayo™ (orforglipron), its once-daily oral weight-loss pill recently approved by the FDA, as well as retatrutide, an investigational therapy currently in late-stage development for obesity and cardiometabolic diseases.

David A. Ricks, Lilly chair and chief executive officer, said the company is investing not only in future medicines but also in advanced manufacturing infrastructure within the United States.

“When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history,” Ricks said, adding that the company intentionally chose to expand domestically.

Indiana Governor Mike Braun welcomed the investment, describing it as another step in strengthening Indiana’s position as a leading hub for life sciences and advanced manufacturing.

According to a forthcoming report from Indiana University Kelley School of Business, Lilly contributes approximately 70% of Indiana’s pharmaceutical GDP, while each Lilly job supports more than two additional jobs across the state. The company also estimates that every dollar spent locally generates up to four dollars in additional economic activity.

Indiana University President Pamela Whitten said Lilly’s continued expansion demonstrates the growing strength of Indiana’s life sciences sector and highlights the importance of collaboration between industry and academic institutions.

Lilly said it plans to break ground on several additional U.S. manufacturing projects later this year as part of its broader domestic expansion strategy.